Extended Data Fig. 7: Modulation of immune effector molecules by CRELD1.

a, Schematic overview of the analysis performed on the 500FG dataset including transcriptome and cytokine production. b–d, Cytokine secretion from PBMC cultures of CRELD1^hi and CRELD1^lo donors after 24 h of stimulation (b) with Pam3Cys for TNF (p = 0.0002) and with B. burgdorferi for (c) IL-1β (p = 0.0087) or (d) IL-6 (p = 0.037, CRELD1^hi n = 9, CRELD1^lo n = 10, unpaired two-sided t-test, *p < 0.05, **p < 0.01, ***p < 0.001). e, CRELD1 expression in PBMC from healthy individuals (n = 638) and juvenile idiopathic arthritis (JIA) patients (n = 161, unpaired two-sided t-test, ***p = 3.1×10^-5). f, GSEA for the ‘cKO down’, WNT signaling, apoptosis and IMM-AGE down signatures in the comparison JIA vs. healthy (p-value derived from statistical summary of GSEA). (Box plots in figure represent median value as well as 25^th-75^th percentiles;, whiskers show the 5^th-95^th percentiles.).